Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 8, 2011

View Archived Issues

Pfizer offers overview of second quarter 2011

Sanofi discovers new lysophospholipid S1P1 receptor agonists

Axin-2 as a key regulator of remyelination

MSX-1 missense substitution linked to familial hypodontia

New voltage-gated calcium channel blockers synthesized

Novel chalcone-linked imidazolone compounds disclosed by CSIR

Addex patents novel metabotropic glutamate mGlu4 receptor modulators

Theravance presents new norepinephrine/serotonin reuptake inhibitors

Palatin Technologies confirms commencement of phase I trial of AZD-2820

AAA obtains rights to anticancer antibody fragment from Dompe

CBio presents data from phase IIa XToll trial in rheumatoid arthritis

Repros Therapeutics reports data from Androxal study in men with type 2 diabetes

Victrelis obtains approval in Canada for chronic hepatitis C

Decitabine plus carboplatin shows promise in phase II ovarian cancer trial

MMRF and Onyx launch carfilzomib expanded access program

Trius Therapeutics reaches agreement with FDA for phase III torezolid trial

Chains of magnetasomes show antitumor effects in preclinical study

MolMed to develop production process for gene therapy for GSK

Alexza resubmits NDA to FDA for AZ-004

Axanum obtains positive agreement for E.U. approval

Genmab reports topline results for ofatumumab in aggressive lymphoma

FDA continues review of EUSA Pharma's BLA for Erwinaze in acute lymphoblastic leukemia

Amgen presents highlights of second quarter 2011

STATegics receives grant to advance product candidates for Friedreich's ataxia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.